Genetic variation in the ADRB2 gene has been hypothesized to have a role in differential response to beta-agonist (BA) therapy in asthma. However, study results have been inconsistent and the issue remains controversial. Furthermore, the impact of ADRB2 genetic variation on BA response in chronic obstructive pulmonary disease (COPD) patients has not been thoroughly studied. We carried out a large pharmacogenetic analysis testing for an association between common ADRB2 polymorphisms and indacaterol response in COPD patients. A total of 648 indacaterol-treated patients enrolled in two large randomized phase III studies were genotyped for the most commonly studied polymorphisms in the ADRB2 gene: Gly16Arg, Gln27Glu, Thr164Ile, and a variant in the 5 0 untranslated region (rs1042711). Our analysis showed little evidence for the association between these ADRB2 variants and indacaterol response, suggesting that ADRB2 genetic variation is unlikely to have a major role in differential response to indacaterol treatment in COPD patients.
Introduction
Genetic variation in the ADRB2 gene has been hypothesized to have a role in differential response to beta-agonist (BA) therapy in asthma. Although a large number of studies have been conducted examining the role of ADRB2 polymorphisms in BA response in asthmatics, results from these studies have been inconsistent and a consensus view is yet to emerge. 1 Some reports indicate that Arg16 homozygous individuals experience worse asthma control than individuals of other Gly16Arg genotype classes after chronic treatment with short-acting beta-agonists (SABAs). [2] [3] [4] Interestingly, single-dose studies of SABAs have reported that Arg16 homozygotes may have better bronchodilator response for short-term treatment. 5, 6 Neither of these observations, however, has been consistently replicated in other studies. 1 Significant associations for the Gln27Glu variant have been less frequently reported, and reports on associations with other variants or haplotype variation have been largely negative or contradictory.
findings. 9, 10 To date, the most definitive study published examined 2250 asthmatics treated with formoterol or salmeterol combined with steroid treatment and found no evidence for association between common ADRB2 polymorphisms and LABA response. 10 In chronic obstructive pulmonary disease (COPD), the impact of ADRB2 genetic variation on BA response has been much less studied than in asthma. Pharmacogenetic study results in COPD populations, similar to those reported previously for asthma populations, have largely failed to identify any association between ADRB2 polymorphisms and BA response. [11] [12] [13] Only a single study addressing the impact of ADRB2 genetic variation on LABA response in COPD has been reported to date.
14 In this study, FEV 1 (forced expiratory volume in 1 sec) changes were assessed following 12 weeks of treatment with salmeterol and steroids in 104 Korean patients with COPD. The results failed to identify any effect for ADRB2 polymorphisms on BA response.
In the present study we conducted a large, retrospective, pharmacogenetic analysis testing for an association between common ADRB2 polymorphisms and response to indacaterol (Onbrez) in COPD patients from two phase III trials. 15, 16 Indacaterol is a novel, long-acting, inhaled BA intended for once-daily treatment in patients with COPD. Our analysis included the two coding variants most often considered in ADRB2 pharmacogenetic studies, Gly16Arg and Gln27Glu, as well as two other variants of interest in or near the ADRB2 gene, Thr164Ile and a variant in the 5 0 untranslated region (UTR; rs1042711).
Materials and methods

Study population
DNA was collected from patients enrolled in two phase III indacaterol clinical trials, QAB149B2335S 15 (clinicaltrials.gov: NCT00463567) and QAB149B2336 16 (clinicaltrials.gov: NCT00567996). Participation in the pharmacogenetic substudy was optional. Study QAB149B2335S was a 26-week study of COPD patients randomized to double-blind indacaterol 150 or 300 mg or placebo, or open-label tiotropium 18 mg, all once daily. Study QAB149B2336 was a 26-week study of COPD patients randomized to double-blind indacaterol 150 mg or placebo once daily, or salmeterol 50 mg twice daily. Both trials evaluated FEV 1 at 12 weeks as the primary end point, as well as other end points over 26 weeks, and showed superiority of indacaterol over placebo and non-inferiority or superiority of indacaterol over active controls. Inclusion criteria were similar across the two trials and included: (a) male and female adults aged X40 years, (b) clinical diagnosis of moderate to severe COPD, (c) smoking history of at least 20 pack-years, (d) post-bronchodilator FEV 1 o80% and X30% of predicted normal value and (e) post-bronchodilator FEV 1 /FVC o70%. Pharmacogenetic analysis focused on the subset of the intent-to-treat population randomized to indacaterol treatment arms (that is, a within-treatment arm analysis), pooled across the two trials. A summary of our study population demographics and end points of interest is presented in Table 1 .
Analysis was performed for all genotyped indacaterol recipients, as well as for 8 subgroups defined by the presence or absence of four criteria: (1) prior LABA or fixed-dose SABA use, (2) prior inhaled corticosteroid use, (3) airflow limitation reversibility (X12% FEV 1 increase post-SABA administration at screening) and (4) current smoking.
Clinical end points
Four efficacy end points were tested for association with ADRB2 genotype: (1) 24-hour post-dose (trough) FEV 1 (l) after 12 weeks of treatment (the primary trial efficacy end point), (2) number of COPD exacerbations during the 26-week Table 1 Study population summary
Number of COPD exacerbations
Change from baseline of morning PEF (L/min) Pharmacogenetic study of indacaterol-treated patients treatment period, (3) change from baseline of morning peak expiratory flow (PEF) (L/min) averaged over 26 weeks and (4) transitional dyspnea index (TDI) score after 26 weeks.
Genetic polymorphisms
We evaluated the two common coding variants most often assessed in ADRB2 pharmacogenetic studies (Gly16Arg, Gln27Glu), the rarer coding variant Thr164Ile and a noncoding variant potentially important to RNA translation, the C4T transition, À47 bp, 5 0 of the ADRB2 translation start. Genotyping methods are available in the Supplementary Information.
Statistical analysis
For the primary analysis, each of the four single-nucleotide polymorphisms (SNPs) in the study was tested individually against each of the four clinical end points using regression modeling. SNPs were tested for the standard additive effect: individuals were coded 0, 1 or 2 for each SNP according to the number of copies of the minor allele that an individual carries. In addition, the Gly16Arg variant was examined in minor allele dominant and recessive models (Gly16Gly individuals vs all others and Arg16Arg individuals vs all others, respectively) to allow more powerful detection of previously reported non-additive effects for this variant. Covariates were included to control for the potential confounding effects of disease severity, ancestry and treatment locale. Population stratification due to ancestry, particularly, was controlled for by including race and country of residence in all models (see Supplementary Information for further details). Multiple testing adjustment was performed by Bonferroni correction. A total of 216 tests were performed (significance threshold 0.05/216 ¼ 0.0002). As these tests are not independent owing to linkage disequilibrium and correlation between end points, this threshold can be considered conservative. With respect to multiple-comparison correction, secondary follow-up analyses (for example, limited haplotype testing-see Supplementary Information) were considered separately.
Results
Genotype quality assessment and linkage disequilibrium Genotyping was performed in both trials for all members of the intent-to-treat population who consented to DNA analysis and submitted a blood sample, resulting in samples from 648 indacaterol recipients available for analysis. High quality genotypes were obtained for all four SNPs attempted and no major deviation from Hardy-Weinberg equilibrium (Po0.001) was seen ( Table 2) . As expected, owing to linkage disequilibrium, significant correlation between genotypes at the studied loci was observed: (a) Gly16Arg (rs1042713) and Gln27Glu (rs1042714) are partially correlated (r 2 ¼ 0.4), and (b) Gln27Glu (rs1042714) and the 5 0 UTR variant (rs1042711) are strongly correlated (r 2 ¼ 0.99). (In adherence to our prespecified analysis plan, we nevertheless report association results for both Gln27Glu and the 5 0 UTR variant.) Because of its relative rarity, the Thr164Ile (rs1800888) variant was not correlated to the other three SNPs.
Genotype/clinical end point association testing results
Results of all association tests are presented for FEV 1 (Table 3) , exacerbations (Table 4) , morning PEF (Supplementary Table 1 ) and TDI (Supplementary Table 2 ). None of the 216 tests performed yielded statistically significant association according to the pre-specified multiplicity-adjusted significance threshold of 0.0002. In particular, the 36 tests (four clinical end points Â nine subpopulations) based on the genotype comparison most frequently discussed in the ADRB2 literature (Arg16Arg homozygotes vs the other two genotype classes; Figure 1 ) failed to achieve even nominal significance (Po0.05) for FEV 1 , exacerbations or change in morning PEF.
Tests of the fourth clinical end point, TDI, yielded several nominally significant association results for the reversible airflow limitation subgroup; however, the direction of effect observed was inconsistent with most prior reports. (Here, patients with the Arg16Arg genotype experienced a higher mean response.) Furthermore, when these associations were examined in the two constituent clinical trials separately, most of the effect was confined to the smaller sample from trial QAB1492336 (N ¼ 84), with the larger sample from trial QAB1492335S (N ¼ 217) showing only modest (if any) association (Supplementary Table 3) .
Similarly negative results were obtained for the other genotype comparisons involving the Gly16Arg polymorphism and for the other three polymorphisms analyzed (Gln27Glu, Thr164Ile and the 5 0 UTR polymorphism). A limited haplotype-based evaluation verified that no major epistatic effects (Po0.01) between key variants (Gly16Arg and Gln27Glu) were missed (Supplementary Table 4) .
Finally, we assessed whether the lack of association detected was possibly because of hidden population stratification by repeating a subset of our analyses on Caucasian Abbreviations: Chr, chromosome; hg19, human genome reference assembly version GRCh37/hg19; HWE, Hardy-Weinberg equilibrium.
Pharmacogenetic study of indacaterol-treated patients subjects only (Caucasians being the most prevalent ancestry in the study). These results are shown in (Supplementary  Table 5 ): No association test P-value exceeded 0.01, confirming the overall negative results.
Discussion
Genetic variation in the ADRB2 gene has been hypothesized to have a role in differential response to BA therapy. Although many pharmacogenetic studies have been performed in asthma, few have been performed in COPD to date. The study described here offers a large (n ¼ 648), well-controlled pharmacogenetic analysis testing for an association between common ADRB2 polymorphisms and indacaterol response in COPD patients, and is the largest LABA/ADRB2 pharmacogenetic study in COPD to date. Our analysis focused on the two coding variants most commonly studied in ADRB2 pharmacogenetic studies, Gly16Arg and Gln27Glu, as well as two other variants of interest in or near the ADRB2 gene. Four different clinical efficacy end points were analyzed: FEV 1 , morning PEF, exacerbations and TDI. Notably, as our study examined indacaterol recipients only, any potential findings may be representative of the natural history of these end points, and may not be treatment specific. Our analysis found little evidence for association between these ADRB2 genetic variants and differential response to indacaterol. Moreover, the analysis was extended to several clinical subgroups thought to be relevant in COPD, including the presence or absence of prior LABA or fixeddose SABA usage, corticosteroid use, airflow limitation reversibility (X12% FEV 1 increase post-SABA administration) Pharmacogenetic study of indacaterol-treated patients and current smoking status, with little evidence of association found in any subgroup. These results are consistent with previous negative findings in both the largest ADRB2/LABA study in asthma 10 and the smaller ADRB2/BA COPD pharmacogenetic reports to date. 11, 13, 14 We conclude that the most frequently studied ADRB2 variants do not have a major role in differential response to indacaterol treatment in moderate-to-severe COPD patients. Pharmacogenetic study of indacaterol-treated patients
